Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6881536 | 0.86 | BCHE (0.63) | KDM4EBCHENPC1RAB9AHPGD | |
| SCHEMBL19225761 | 0.82 | NPC1 (0.60) | KDM4ENPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL13778650 | 0.82 | FDPS (0.45) | KDM4ENPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL24697057 | 0.81 | FDPS (0.71) | NPC1RAB9AHPGDSMN1; SMN2MEN1 | |
| SCHEMBL4772214 | 0.81 | AR (0.49) | KDM4ENPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL23206799 | 0.81 | KDM4E (0.59) | KDM4EMEN1KMT2A | |
| SCHEMBL19225758 | 0.80 | NPC1 (0.48) | KDM4ENPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL31444153 | 0.80 | BCHE (0.63) | KDM4EBCHENPC1RAB9AHPGD | |
| SCHEMBL6035592 | 0.80 | BCHE (0.63) | KDM4EBCHENPC1RAB9AHPGD | |
| SCHEMBL16610000 | 0.79 | TSHR (0.58) | KDM4EHTR1AADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. (US) | 2022-12-15 | — | — | US | disclosed |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | Janssen Biopharma, Inc. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. | 2017-10-05 | — | — | US | disclosed |
| US-9724351-B2 | Compounds for the treatment of paramoxyvirus viral infections | ALIOS BIOPHARMA, INC. (US) | 2017-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | KDM4E 3430/4885BCHE 4073/4885NPC1 2197/4885 |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | MAVS, SARS1, ZC3HAV1 | KDM4E 3430/4885BCHE 4073/4885NPC1 2197/4885 |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | KDM4E 3430/4885BCHE 4073/4885NPC1 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.